Zydus Cadila gets USFDA final approval for Deferasirox tablets

Pharma major, Zydus Cadila informed the bourses after trading hours on Thursday that the company has received a final approval from USFDA to market Deferasirox tablets for oral suspension in the strengths of 125 mg, 250 mg and 500 mg. The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

Deferasirox binds to iron and removes it from the bloodstream and is also, used to treat iron overload caused by blood transfusions in adults and children who are at least two years old. Besides, it is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.

The group now has 289 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare Limited manufactures and markets healthcare solutions ranging from formulations, active pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to cosmeceuticals. Its products are available in tablets, capsules, injections, liquids, dry syrups, powders, granules and ointments.

At 10.30 am on Friday, the stock was trading at Rs 322.80, up by 0.37 per cent or Rs 1.20 per share. The 52-week high is recorded at Rs 378 and the 52-week low is Rs 206.45 on BSE.